Filing identity and reporting period
The supplied filing is Jupiter Wellness, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2023, filed August 14, 2023. This does not match the request metadata naming BONK, INC.; verify the issuer before relying on this summary.
Jupiter Wellness reported two segments: wellness and therapeutic products, and theme-park merchandise through SRM Entertainment.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $2.37 million | $3.00 million | $3.49 million | $3.72 million |
| Gross profit | $504,000 | $505,000 | $750,000 | $622,000 |
| Gross margin | 21.3% | 16.8% | 21.5% | 16.7% |
| Operating expenses | $2.00 million | $1.40 million | $3.50 million | $4.41 million |
| Net loss | $360,000 | $1.44 million | $1.67 million | $4.36 million |
| Operating cash flow | Not separately stated | Not separately stated | $(2.10) million | $(3.71) million |
- Q2 revenue declined about 21% year over year; six-month revenue declined about 6%. Six-month gross profit increased about 21%, reflecting lower cost of sales.
- Q2 net loss narrowed substantially, but results included a $1.17 million unrealized gain on Chijet securities. Six-month other income likewise included this non-cash gain; it should not be treated as operating performance or cash generation.
- At June 30, cash was $2.77 million and marketable securities were $4.58 million. Current assets were $9.17 million, current liabilities $5.00 million, and working capital $4.17 million.
- Debt included $2.00 million of related-party convertible notes, $49,615 of SBA debt, and lease liabilities totaling about $609,000. The convertible notes mature January 31, 2024, bear 8% interest, and have a $2.79 conversion price, subject to adjustment under specified default conditions.
- Net proceeds from the January 2023 equity and warrant offerings were $3.45 million. Common shares outstanding rose from 22.34 million at December 31, 2022 to 27.15 million at June 30, 2023. The company also had 24.59 million warrants outstanding at quarter-end.
Management commentary, outlook, and material items
- Management described product development and licensing plans for products including Photocil, JW-700, JW-500, NoStingz, and JW-110. It said JW-700 was licensed to Taisho, with a planned 2024 commercial launch, and that licensing agreements for JW-700 and Photocil had been signed in India. No financial guidance or quantified outlook was provided.
- On July 10, 2023, the company entered an agreement to acquire Safety Shot intellectual property for $200,000 cash and five million shares. The transaction had not closed and no consideration had been exchanged as of the filing.
- The company disclosed substantial accumulated deficits and continuing operating cash outflows. It stated that these conditions raised substantial doubt about its ability to continue as a going concern.
- The $4.58 million Chijet securities balance arose from shares received in connection with the Chijet business combination and a separate share purchase. The filing recorded an unrealized gain of $1.17 million and a $233,377 contingent bonus liability for CEO Brian John tied to investment profits.
- The company reported no impairment in the first half of 2023. Prior-period comparability includes a $1.00 million note impairment in the first half of 2022.
- A lawsuit involving the company, its CEO, and other parties was dismissed with prejudice in February 2023 following settlement; the filing says the company paid no settlement amount.
Controls, risks, and reporting caveats
- The filing’s controls discussion is internally inconsistent: it first says the certifying officers concluded disclosure controls were effective, then states management concluded they were ineffective. Management also described remediation efforts addressing segregation of duties and documentation weaknesses. Clarification is warranted.
- Some MD&A figures and labels appear inconsistent with the financial statements. For example, the six-month discussion misstates cost of sales, and the cash-flow statement’s investing and financing captions appear mismatched to the listed transactions. The audited or unaudited primary statements and notes should be checked against the underlying filing.
- The company’s products rely on contract manufacturers, distributors, and purchase orders; SRM has no long-term customer agreements. The filing provides no detailed risk-factor discussion, citing the company’s smaller-reporting-company status.
Most important facts for investors to verify
- Confirm the issuer: the filing identifies Jupiter Wellness, Inc., not BONK, INC.
- Assess going-concern risk, operating cash burn, and the company’s ability to meet the January 2024 convertible-note maturity.
- Separate recurring operating results from the unrealized Chijet gain, and verify the securities’ valuation and liquidity.
- Review dilution from outstanding warrants, the 2023 share issuance, and the proposed five-million-share Safety Shot consideration.
- Resolve the contradictory disclosure-controls conclusion and reconcile apparent MD&A and cash-flow presentation errors to the complete filed statements.